Thank you very much.
Maybe I'll go back to Mr. Adams for a second. You brought it up in your opening statement when you talked about whether organizations are taking money from pharmaceutical companies, and that's a bad thing. One of your last recommendations was to create some kind of funding for patient groups so that they can speak on behalf of their organizations. Can you talk to that one just a little bit more?